Forbes

Medtronic's CoreValve Gains New Indication For High Risk Patients

Medtronic's CoreValve system today gained a second indication from the FDA for use in patients with severe aortic stenosis who are at high risk for surgery. The transcatheter aortic valve replacement ...
TCTMD

Medtronic CoreValve® System Gains CE Mark for New Direct Aortic Approach to Transcatheter Aortic Valve Implantation

MINNEAPOLIS – Medtronic, Inc.today announced it has received CE (Conformité Européenne) Mark for the Medtronic CoreValve® System to be delivered using direct aortic access. The Medtronic CoreValve ...
TCTMD

Medtronic Begins Global Clinical Trial Evaluating CoreValve® System Implantation in Intermediate-Risk Patients

MINNEAPOLIS– Medtronic, Inc. today announced the first patient enrollment in a global, multicenter, randomized clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve ...
Medscape

At long last, CoreValve trial gets green light from FDA

Minneapolis, MN - The long-awaited US trial of the CoreValve transcatheter aortic-valve system is set to begin soon now that the FDA has granted Medtronic an investigational device exemption (IDE) for ...
Medscape

Pacemaker Implants With Corevalve Edge Lower

October 10, 2012 (London, United Kingdom) — New data--including results from registries in Latin America, Asia, and parts of Europe--suggest that rates of pacemaker implantation following ...
Forbes

Medtronic's Two Year Study Reveals Positive Results For Its CoreValve System

Medtronic's CoreValve transcatheter aortic valve replacement system continued to report positive data at two years for high-risk patients. The study shows the efficacy of TAVR for high-risk patients ...
MD&M East

New FDA Indication for Medtronic CoreValve: It's a First

FDA has cleared the way for Medtronic's CoreValve to be used in more patients in the United States. The agency on Monday announced a new indication for CoreValve in which the device can be used in ...
Nasdaq

Study Shows Medtronic's CoreValve TAVR Device Has Consistent And Cost Effective Performance

Medtronic, Inc. 's ( MDT) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ...
Business Wire

Medtronic Completes Enrollment of Extreme Risk Patient Group in CoreValve® U.S. Pivotal Trial

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The company also received ...
EurekAlert!

Results of the COREVALVE EXTREME RISK trial presented at TCT 2013

SAN FRANCISCO, CA – October 29, 2013 – In a clinical trial, a self-expanding transcatheter aortic valve met the key performance objective of reducing death and stroke in patients with severe aortic ...
MD&M East

Medtronic Hit with Serious CoreValve-related Recall

A little more than a month after the medtech giant received FDA approval for its CoreValve Evolut R valve, a delivery device related to the product is the subject of a Class I-level recall. Qmed Staff ...